Mylan Gets Tentative Approval for Generic Depakote
Posted on: Thursday, 15 March 2007, 09:01 CDT
Mylan Pharmaceuticals, a subsidiary of Mylan Laboratories, has received tentative approval from the FDA for its generic version of Abbott's Depakote extended release tablets.
Mylan has received the tentative approval for the drug in 250mg and 500mg strengths. Depakote ER is approved in the US for the treatment of bipolar disorder, epilepsy, and the prevention of migraine in adults.
Divalproex sodium ER tablets are the generic version of the drug, which had US sales of approximately $698 million for the same strengths for the 12-month period ending December 31, 2006, according to IMS Health.
Source: Datamonitor
Related Articles
- Mylan Announces Tentative Approval for Ondansetron Hydrochloride Tablets
- Mylan CEO's Salary Rises, Compensation Falls
- Fla. Lawsuit Alleges Mylan Inflated Prices: ; W.Va. Could Also Be Affected, Delegate Says
- Mylan Profits Best Forecasts As Company Shrugs Off FDA Advisory on Patch
- Drugmaker Mylan Laboratories Reports Decline in Earnings, Revenue
- Billionaire Icahn Sells Bulk of Shares Back to Mylan
- Canonsburg, Pa.-Based Mylan's Shares Get Boost on Profits Expectation
- Two Mylan Insiders Dropped From Board
- Mylan Receives Approval for Mercaptopurine Tablets USP, 50 Mg
- Mylan Gets Tentative Generic Approval
Rating: 3.8 / 5 (6 votes)
 |
 |
Rate this article:
User Comments (0)
RSS Feeds